Enanta (ENTA) Pushes Higher in Pre-Market Trading for June 22

Equities Staff  |

Shares of Enanta Pharmaceuticals Inc (NASDAQ:ENTA) are on the move in pre-market trading for June 22.

Ahead of the market's open, Enanta stock is up 6.68% from the previous session’s close.

Enanta lost $0.45 in the last session and looks to correct itself today.

For technical charts, analysis, and more on Enanta visit the company profile.

Pre-market prices and movements as of 07:22:56 est.

About Enanta Pharmaceuticals Inc

Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. Enanta's research and development efforts have produced clinical candidates for the following disease targets: respiratory syncytial virus (RSV), non-alcoholic steatohepatitis (NASH) and hepatitis B virus (HBV). Enanta is also conducting research in human metapneumovirus (hMPV) and emerging coronaviruses, including SARS-CoV-2.

To get more information on Enanta Pharmaceuticals Inc and to follow the company's latest updates, you can visit the company's profile page here: Enanta Pharmaceuticals Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

The Best Laid Plans of Mice and Men — Part II
Why I’m Buying the 'New' Value Stocks
Investors Must Understand 5G Wireless Growth Wave: Jeff Kagan
'Goldilocks' Stocks Will Define This Decade



Market Movers

Sponsored Financial Content